{Reference Type}: Clinical Trial, Phase II
{Title}: Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
{Author}: Wagner-Johnston ND;Schuster SJ;deVos S;Salles G;Jurczak WJ;Flowers CR;Viardot A;Flinn IW;Martin P;Xing G;Rajakumaraswamy N;Gopal AK;
{Journal}: Leuk Lymphoma
{Volume}: 62
{Issue}: 5
{Year}: 05 2021
暂无{DOI}: 10.1080/10428194.2020.1855344
{Abstract}: The phase 2 study of idelalisib monotherapy for indolent non-Hodgkin lymphomas (iNHLs) was completed in 2018; final efficacy and safety data with up to 6.7 years long-term follow-up are reported. Patients with iNHL refractory to both rituximab and an alkylating agent were enrolled and received 150 mg idelalisib twice daily (N = 125). Idelalisib resulted in an overall response rate of 57.6% with 34.4% continuing therapy for ≥12 months. The median progression-free survival and duration of response were 11.0 and 11.8 months for follicular lymphoma, 22.2 and 20.4 months for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM), and 6.6 and 18.4 months for marginal zone lymphoma (MZL). Median overall survival after extended follow-up was 48.6 (95% CI 33.9, 71.7) months. Long-term follow-up did not reveal new safety concerns. These data indicate beneficial outcomes with longer follow-up after idelalisib for treatment of iNHL including in patients with LPL/WM and MZL.